Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution

• Published in: Modern pathology Vol. 26; no. 7; pp. 922 - 929
• Main Authors: Boots-Sprenger, Sandra H E, Sijben, Angelique, Rijntjes, Jos, Tops, Bastiaan B J, Idema, Albert J, Rivera, Andreana L, Bleeker, Fonnet E, Gijtenbeek, Anja M, Diefes, Kristin, Heathcock, Lindsey, Aldape, Kenneth D, Jeuken, Judith W M, Wesseling, Pieter
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.07.2013; Elsevier Limited
• Subjects: 692/53/2422; 692/699/67/1922; 692/700/139/422; Adult; Age; Biomarkers, Tumor - genetics; Brain cancer; Brain Neoplasms - classification; Brain Neoplasms - genetics; Brain Neoplasms - mortality; Chromosome Deletion; Chromosomes, Human, Pair 1 - genetics; Chromosomes, Human, Pair 19 - genetics; DNA Methylation; DNA Modification Methylases - genetics; DNA Repair Enzymes - genetics; Female; Gene Deletion; Glioma - classification; Glioma - genetics; Glioma - mortality; Hospitals; Humans; Isocitrate Dehydrogenase - genetics; Kaplan-Meier Estimate; Laboratory Medicine; Male; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Mutation; Nervous system; Neurology; original-article; Pathology; Pathology, Molecular; Patients; Prognosis; Promoter Regions, Genetic; Tumor Suppressor Proteins - genetics; Tumors; United States > US; Netherlands; glioma; molecular markers; complete 1p/19q co-deletion

The histopathological diagnosis of diffuse gliomas often lacks the precision that is needed for tailored treatment of individual patients. Assessment of the molecular aberrations will probably allow more robust and prognostically relevant classification of these tumors. Markers that have gained a lo...